Key facts
- Newcode Bio’s last known valuation is $547.8M (Mar 2026).
- It has raised $213.1M; the latest was Later Stage VC ($89.9M) in Mar 2026.
- Notable investors include Puhua Capital, CMG SDIC Fund, Beijing Shengshi Hongming Investment Fund Management, CITIC Medical & Heath Group, CS Capital (Beijing) — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Newcode Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Newcode Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Newcode Bio
Developer of biopharmaceutical modalities intended for targeted therapy and addressing clinical needs. The company offers an innovative biologic drug and integrated research capabilities spanning genetic engineering, cell culture, toxin coupling, formulation work, and preclinical to clinical evaluation, enabling healthcare researchers and pharmaceutical organizations to pursue therapeutic development with consistent scientific rigor.
- Sector
- Healthcare
- HQ
- Shaoxing, China
- Founded
- 2017
- Employees
- 104
- Website
- novocodex.cn/
- Ownership
- Privately Held (backing)
Newcode Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Newcode Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Newcode Bio in its N-PORT filings yet. We sweep new filings monthly.